OHI — Omega Healthcare Investors, Inc.

Omega Healthcare Investors (OHI) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $328 million, up from $283 million in Q2 2025.
• Net Income: $363 million ($1.19 per share), compared to $137 million ($0.46 per share) in Q2 2025, largely due to a $247 million gain from asset sales.
• Adjusted Funds from Operations (AFFO): $261 million ($0.83 per share), reflecting strong year-over-year growth but flat sequentially due to asset sales.
• Funds Available for Distribution (FAD): $248 million ($0.78 per share).
• Debt Management: Debt reduced to $6 million on a $2 billion revolver, with a fixed charge coverage ratio of 6.5x and leverage at 3.3x.
• Dividend Increase: A $0.01 increase announced, reflecting confidence in financial stability.

2. Strategic Updates and Business Highlights

• Portfolio Transition: Significant asset sales, including 18 CommuniCare facilities for $480 million, aimed at strengthening credit profiles and reallocating capital for higher returns.
• Operator Performance: Transitioned 20 facilities from Ciena to Saber and HHC, enhancing overall credit without negative FAD impact.
• Investment Activity: Closed $470 million in new investments YTD, with $218 million in Q2, including acquisitions in senior housing and skilled nursing facilities.
• Pipeline Strength: A robust pipeline of transactions expected to increase in volume through the end of 2026, focusing on both U.S. and U.K. markets.

3. Forward Guidance and Outlook

• Adjusted FFO Guidance: Increased to a range of $3.22 to $3.26 per share, reflecting a slight upward revision from previous estimates.
• Investment Expectations: Anticipated deployment of proceeds from asset sales into new investments, expected to support growth in Q4 2026 and into 2027.
• Long-term Growth: Management expressed confidence in achieving mid-single-digit annualized FAD growth, with potential for higher growth in favorable conditions.

4. Bad News, Challenges, or Points of Concern

• Impact of Asset Sales: The $563 million in asset sales during Q2 is expected to create a temporary headwind for earnings in Q3.
• Operator Coverage: While overall coverage is improving, there are still concerns regarding specific operators, although no major issues were identified in the current portfolio.
• Market Competition: Increasing competition for acquisitions, particularly in the U.K. and senior housing sectors, may challenge sourcing transactions with embedded upside.

5. Notable Q&A Insights

• RIDEA Structure: Management discussed the potential for future RIDEA transactions in the U.K., emphasizing the alignment of interests with operators and the flexibility of capital deployment.
• Texas Market: Despite historically low occupancy in Texas, management remains confident in the state’s recovery potential and overall portfolio coverage.
• Saber Relationship: The relationship with Saber is seen as a model for future partnerships, with a focus on alignment of interests and operational quality.
• Regulatory Environment: Positive momentum in staffing recovery and regulatory changes were noted, although potential risks from fraud and abuse investigations in healthcare were acknowledged.

Overall, Omega Healthcare Investors demonstrated strong financial performance in Q2 2026, with strategic asset management and a robust investment pipeline positioning the company for future growth, despite some challenges related to asset sales and market competition.